Archives
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
br The potential of EPA
2022-09-21

The potential of EPA-Ffar4 signaling as a novel intervention for HFpEF Conclusions and future directions Optimization of ω3-PUFA/EPA-therapy based upon titration to achieve therapeutic levels: A pressing clinical challenge is to continue to define the benefit of ω3-PUFA/EPA-therapy. Recent ana
-
The G protein coupled receptor GPR also called
2022-09-21

The G protein-coupled receptor, GPR40 (also called FFAR1) responds to medium and long chain unsaturated fatty acids, resulting in increase of insulin secretion during elevated glucose levels. The glucose dependency of insulin secretion makes this receptor a very good target for developing therapies
-
We reveal that the four
2022-09-20

We reveal that the four well known vertebrate families of KAT enzymes (GNAT, MYST, P300/CBP, Basal transcription factor/nuclear receptor co-activator) seem to be conserved (Karmodiya et al., 2014; Roth et al., 2001; Sheikh & Akhtar, 2018) in the mangrove rivulus, together with Camello, a potential n
-
Our previous study provided some evidence that the
2022-09-20

Our previous study provided some evidence that the pre-treatment of livers with rapamycin induces the expression of HO-1 and Prx-1 (Kist et al., 2012). The present results define the dose-response curve for the induction of HO-1 and Prx-1 expression by rapamycin in normal hepatocytes. While, in the
-
br Pathophysiology of glaucoma Glaucoma is
2022-09-20

Pathophysiology of glaucoma Glaucoma is a group of optic neuropathies defined by progressive degeneration of RGCs and their DLPC synthesis in the optic nerve, which leads to irreversible loss of vision [3,8,9]. RGC degeneration is often significantly advanced before changes in visual acuity and e
-
We observed that the Toc G domain recognizes the
2022-09-20

We observed that the Toc159G domain recognizes the N-terminal portion of the transit peptide of pSSU with a dissociation constant of 70 μM (Fig. 2; Table 1), while a tenfold higher KD was obtained for the phosphorylated C-terminal region. In turn, the homodimer of Toc34G recognizes the phosphorylat
-
Targeting MCTs is likely to have dramatic effects on
2022-09-20

Targeting MCTs is likely to have dramatic effects on lactate-dependent metabolic symbiosis described in the previous paragraphs. A plethora of MCT inhibitors have been described, including α-cyano-4-hydroxycinnamate (CHC) [59], organomercurials [60], stilbene disulfonates [60], and other second-gene
-
br Lactate metabolism L Lactate is
2022-09-20

Lactate metabolism L-Lactate is an intermediate metabolite in glucose metabolism. Glucose can be broken down to pyruvate, and pyruvate can be either further oxidized to acetyl-CoA and enter the TCA cycle, or reduced to L-lactate by lactate dehydrogenase (LDH). In turn, LDH can oxidize L-lactate t
-
A high throughput screening campaign of the Lilly
2022-09-19

A high-throughput screening campaign of the Lilly corporate compound collection led to the discovery of as potent and selective inhibitor of GlyT1 (IC=45nM, GlyT2 IC>30,000nM). In addition to the characteristic -methyl glycine moiety as acidic head group and the novel ethanolamine linker, also co
-
PTMs have been shown to influence transporter kinetics both
2022-09-19

PTMs have been shown to influence transporter kinetics, both directly and indirectly (Xu & You, 2017). They do not just regulate the innate structure-function relationship driven by a transporter's global architecture, but rather are also able to regulate this relationship down to the resolution of
-
The association between mental disorders
2022-09-19

The association between mental disorders and smoking was firmly established, and their inter-relationship was due to the reciprocal causal effects (Tjora et al., 2014). Previous research found that negative affect and the urge to smoke as well as the urge to smoke and nicotine dependence had signifi
-
br Acknowledgements This work is supported by the Cognitive
2022-09-19

Acknowledgements This work is supported by the Cognitive Sciences and Technologies Council of Iran (CSTC, Grant No. 95P31), the Iran National Science Foundation (INSF) and the Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran. The authors wish to thank Dr. Ayat Kaeidi for his
-
WAY-100635 Previous study demonstrated that Hcy elevated org
2022-09-17

Previous study demonstrated that Hcy elevated organ culture-induced up-regulation of ETB receptor in VSMCs (Chen et al., 2016a; Chen et al., 2016b). Many signaling pathways were involved in Hcy-induced up-regulation of ETB receptor in VSMCs, such as ERK1/2/NF-κB signaling pathway, Sirt1/NF-κB signal
-
Sodium Phenylbutyrate synthesis H R antagonism can prevent s
2022-09-17

H3R antagonism can prevent seizure development and improve working memory through the activation of histaminergic neurons (Huang et al., 2004, Zhang et al., 2003). In addition, we have recently found that H3R antagonism protects against ischemia-reperfusion injury via histamine-independent mechanism
-
Hesperadin sale The only approved H R antagonist inverse ago
2022-09-17

The only approved H3R antagonist/inverse agonist is BF2.649 (1- 3-[3-(4-chlorophenyl)propoxy]propyl piperidine), developed by Bioprojet and known as pitolisant (Wakix®). It was approved by the European Medicines Agency in March 2016 and marketed in the European Union to be used in narcolepsy with or
16424 records 395/1095 page Previous Next First page 上5页 391392393394395 下5页 Last page